Treatment of heparin-induced thrombocytopenia

被引:36
作者
Dager, WE
White, RH
机构
[1] Univ Calif Davis, Davis Med Ctr, Dept Pharmaceut Serv, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA
[3] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA
[4] Univ Calif Davis, Davis Med Ctr, Anticoagulat Serv, Sacramento, CA 95817 USA
关键词
antithrombins; argatroban; bivalirudin; danaparold; fondaparinux; heparin-induced thrombocytopenia; lepirudin; melagatran;
D O I
10.1345/aph.1A204
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To describe heparin-induced thrombocytopenia (HIT or HIT-2), an immune-mediated adverse reaction to heparin or low-molecular-weight heparin. Available treatment options and considerations in developing a therapy approach are discussed. DATA SOURCES: A search of the National Library of Medicine (1992-June 2001) was done to identify pertinent literature. Additional references were reviewed from selected articles. STUDY SELECTION: Articles related to laboratory recognition and treatment options of HIT, including the use of agents in selected clinical conditions, were reviewed and included. CONCLUSIONS: HIT is a rare but potentially severe adverse reaction to heparin that was, until recently, poorly understood and had limited treatment options. Recent advances describing the recognition and clinical manifestations of immune-mediated HIT, including recently available antithrombotic treatment options, have dramatically changed outcomes for patients having this syndrome.
引用
收藏
页码:489 / 503
页数:15
相关论文
共 98 条
[1]   Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies [J].
Ahmad, S ;
Jeske, WP ;
Walenga, JM ;
Hoppensteadt, DA ;
Wood, JJ ;
Herbert, JM ;
Messmore, HL ;
Fareed, J .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 (04) :259-266
[2]   Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications [J].
Ahmad, S ;
Ahsan, A ;
George, M ;
Iqbal, O ;
Jeske, WP ;
McKenna, R ;
Lewis, BE ;
Walenga, JM ;
Fareed, J .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 (04) :252-258
[3]   Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia [J].
Amiral, J ;
Wolf, M ;
Fischer, AM ;
BoyerNeumann, C ;
Vissac, AM ;
Meyer, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) :954-959
[4]   Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].
Antman, EM .
CIRCULATION, 1996, 94 (05) :911-921
[5]   Heparin-induced thrombocytopenia in coronary bypass surgery [J].
Arnoletti, JP ;
Whitman, GJR .
ANNALS OF THORACIC SURGERY, 1999, 68 (02) :576-578
[6]  
Bata I, 1997, CIRCULATION, V96, P769
[7]   Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin [J].
Bates, SM ;
Weitz, JI .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (8B) :12P-18P
[8]   TREATMENT WITH BIVALIRUDIN (HIRULOG) AS COMPARED WITH HEPARIN DURING CORONARY ANGIOPLASTY FOR UNSTABLE OR POSTINFARCTION ANGINA [J].
BITTL, JA ;
STRONY, J ;
BRINKER, JA ;
AHMED, WH ;
MECKEL, CR ;
CHAITMAN, BR ;
MARAGANORE, J ;
DEUTSCH, E ;
ADELMAN, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (12) :764-769
[9]   A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina [J].
Bittl, JA ;
Feit, F .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (8B) :43P-49P
[10]   Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty [J].
Bittl, JA ;
Ahmed, WH .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (8B) :50P-56P